Ikena Oncology (NASDAQ:IKNA) PT Lowered to $4.00

Ikena Oncology (NASDAQ:IKNAFree Report) had its target price reduced by HC Wainwright from $11.00 to $4.00 in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.30) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.20) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.40) EPS.

Separately, Wedbush reaffirmed an outperform rating and issued a $8.00 price target on shares of Ikena Oncology in a research note on Tuesday, May 14th.

Check Out Our Latest Report on IKNA

Ikena Oncology Price Performance

Shares of IKNA stock opened at $1.77 on Wednesday. The stock has a market cap of $85.42 million, a PE ratio of -1.12 and a beta of 0.33. The stock has a 50-day moving average of $1.36 and a 200-day moving average of $1.53. Ikena Oncology has a one year low of $1.02 and a one year high of $7.38.

Ikena Oncology (NASDAQ:IKNAGet Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.12. As a group, research analysts anticipate that Ikena Oncology will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On Ikena Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. grew its position in shares of Ikena Oncology by 5.2% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 407,900 shares of the company’s stock valued at $1,766,000 after purchasing an additional 20,000 shares during the period. CHI Advisors LLC grew its position in shares of Ikena Oncology by 2.8% in the 3rd quarter. CHI Advisors LLC now owns 2,180,934 shares of the company’s stock valued at $9,443,000 after purchasing an additional 58,894 shares during the period. Laurion Capital Management LP grew its position in shares of Ikena Oncology by 3.3% in the 3rd quarter. Laurion Capital Management LP now owns 534,657 shares of the company’s stock valued at $2,315,000 after purchasing an additional 17,094 shares during the period. OUP Management Co. LLC acquired a new position in shares of Ikena Oncology in the 3rd quarter valued at approximately $116,000. Finally, SG Americas Securities LLC grew its position in shares of Ikena Oncology by 88.5% in the 4th quarter. SG Americas Securities LLC now owns 20,222 shares of the company’s stock valued at $40,000 after purchasing an additional 9,495 shares during the period. 75.00% of the stock is currently owned by institutional investors and hedge funds.

About Ikena Oncology

(Get Free Report)

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.

Featured Articles

Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.